Less Ads, More Data, More Tools Register for FREE

Pin to quick picksApax Global Alpha Regulatory News (APAX)

  • This share is currently suspended. It was suspended at a price of 164.40
  • There is currently no data for APAX

Form 8.3 - APAX LN

14 Aug 2025 15:30

RNS Number : 3582V
Syquant Capital
14 August 2025
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Identity of the person whose positions/dealings are being disclosed:

SYQUANT CAPITAL

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Apax Global Alpha Limited

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

August 13, 2025

(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?

NO

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ordinary NPV

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

4,412,253

0.91%

 

 

(2) Derivatives (other than options):

836,450

0.17%

 

(3) Options and agreements to purchase/sell:

 

 

 

 

TOTAL:

5,248,703

1.08%

 

 

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

 

 

 

 

 

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Ordinary NPV

 

CFD

 

increasing a long position

 

2,800,000

 

162.6 GBp

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

N/A

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

N/A

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

August 14, 2025

Contact name:

Laurent Boscherel

Telephone number:

+33 1 42 56 56 27

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETSFUSULEISEEA
Date   Source Headline
26th Mar 20201:12 pmRNSStatement regarding COVID-19
20th Mar 20204:46 pmRNSSecond Price Monitoring Extn
20th Mar 20204:36 pmRNSPrice Monitoring Extension
20th Mar 202010:20 amRNSSecond Price Monitoring Extn
20th Mar 202010:16 amRNSPrice Monitoring Extension
19th Mar 202012:07 pmRNSSecond Price Monitoring Extn
19th Mar 202012:02 pmRNSPrice Monitoring Extension
17th Mar 20204:00 pmRNSDirector/PDMR Shareholding
17th Mar 20204:00 pmRNSDirector/PDMR Shareholding
13th Mar 202012:07 pmRNSSecond Price Monitoring Extn
13th Mar 202012:02 pmRNSPrice Monitoring Extension
12th Mar 202012:07 pmRNSSecond Price Monitoring Extn
12th Mar 202012:02 pmRNSPrice Monitoring Extension
11th Mar 20207:00 amRNSDirector/PDMR Shareholding
9th Mar 20207:00 amRNSNotice of Results
5th Mar 20202:17 pmRNSPurchase of Ordinary Shares under IM Agreement
5th Mar 20207:00 amRNSNotice of Investor Day
3rd Mar 202012:02 pmRNSPrice Monitoring Extension
3rd Mar 20207:00 amRNSUpdated Key Information Document
3rd Mar 20207:00 amRNSNotice of AGM
3rd Mar 20207:00 amRNS2019 Annual Dividend
3rd Mar 20207:00 amRNS2019 Final Results
3rd Mar 20207:00 amRNS2019 Annual Report and Accounts
14th Feb 20207:00 amRNSDirector Change - Appointment
4th Feb 20207:00 amRNSApax Funds' Valuations as at 31 December 2019
15th Jan 20203:31 pmRNSPDMR Shareholding
15th Jan 20203:30 pmRNSPDMR Shareholding
26th Nov 20194:35 pmRNSPrice Monitoring Extension
11th Nov 20197:00 amRNSNotice of Annual Results
6th Nov 20197:00 amRNSQuarterly Results for 30 September 2019
16th Oct 20197:00 amRNSApax Funds' Valuations as at 30 September 2019
27th Sep 20194:40 pmRNSSecond Price Monitoring Extn
27th Sep 20194:35 pmRNSPrice Monitoring Extension
16th Sep 201910:37 amRNSNotice of Quarterly Results - September 2019
20th Aug 20199:17 amRNSPDMR Dealing - Share Transfers
14th Aug 20197:00 amRNS2019 Interim Dividend
14th Aug 20197:00 amRNS2019 Interim Results Highlights
14th Aug 20197:00 amRNS2019 Interim Report and Accounts
1st Aug 20197:00 amRNSApax Digital Fund Valuation as at 30 June 2019
30th Jul 20197:00 amRNSApax Funds' Valuations as at 30 June 2019
15th Jul 201910:59 amRNSProposed commitment to the Apax X Fund
22nd May 20197:00 amRNSAGA Investor Day
17th May 20194:30 pmRNSDirector/PDMR Shareholding
9th May 20197:00 amRNSNotice of Interim Results - June 2019
8th May 201912:28 pmRNSResult of AGM Replacement
8th May 20197:00 amRNSQuarterly Results for 31 March 2019
7th May 20196:30 pmRNSResult of AGM
5th Apr 20195:32 pmRNSApax Funds' Valuations as at 31 March 2019
19th Mar 20192:39 pmRNSNotice of Investor Day
18th Mar 20199:59 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.